Carboplatin

Catalog No.S1215 Synonyms: JM-8, CBDCA, NSC 241240

Carboplatin Chemical Structure

Molecular Weight(MW): 371.25

Carboplatin is a DNA synthesis inhibitor by binding to DNA and interfering with the cell's repair mechanism in A2780, SKOV-3, IGROV-1, and HX62 cells.

Size Price Stock Quantity  
USD 77 In stock
USD 107 In stock
USD 167 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • (A) The BRCA1-mutated TNBC cell lines MDA-MB-436 and HCC1937 were treated with CBP (10 μM) plus GEM (100 nM) combined with or without olaparib (10 μM) for the indicated times, and then, the cell viability was determined with an MTT assay. The results show data from six independent experiments expressed as the mean ± SD. p < 0.05.

    Sci Rep, 2017, 7:42319. Carboplatin purchased from Selleck.

    Detection of apoptotic responses was found to increase in epimorphin-treated  A1847 with increasing concentrations of carboplatin compared to those of the untreated controls. Data were normalized to the controls and are represented as means ± S.D. [*p<0.05 compared with control]. Images of apoptotic cells were captured at 10X magnification, with at least 3 images per well, using an upright phase-contrast microscope (T3.15A; Fisher Scientific).

    PLoS One 2012 8, e72637. Carboplatin purchased from Selleck.

  • A. MCF10A-Ras overexpressing a vector control or the gene of interest (GeneX), or MCF7 expressing a scramble or a siRNA for the geneX were treated with DMSO or with Carboplatin for 24h. Resistant colonies were allowed to grow for 2 weeks, and are then stained with Crystal Violet. B. Quantification of the results.

     

     

    Dr. Helen Sadik of Johns Hopkins University. Carboplatin purchased from Selleck.

    Cells were seeded in 96 well paltes, and then treated with the indicated concentration of Carboplatin for 48h. Cell survival was measured by a standarad MTT assay.

     

     

    Dr. Helen Sadik of Johns Hopkins University. Carboplatin purchased from Selleck.

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Carboplatin is a DNA synthesis inhibitor by binding to DNA and interfering with the cell's repair mechanism in A2780, SKOV-3, IGROV-1, and HX62 cells.
Features A DNA synthesis inhibitor.
Targets
DNA synthesis [1]
(A2780, SKOV-3, IGROV-1, HX62 cells)
In vitro

Carboplatin exhibits an inhibitory effect on cell proliferation in a human ovarian cancer cell line panel, including A2780, SKOV3, and IGROV-1 cells with IC50 of 6.1 μM, 12.4 μM and 2.2 μM, respectively. [1] Carboplatin also show the anti-proliferative activities in lung carcinoid cell line, such as UMC-11, H727, and H835 cells with IC50 of 36.4 μM, 3.4 μM and 35.8 μM, respectively. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Tca8113/ut  NWPNXWp6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2W4RlIuOjYkgJpOwG0> MXK3NkBp NYPheHF3cW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= M4nZWFI3OTN5MUC1
Tca8113/CBP  M{XY[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTkNk0zPeLCid88US=> M1LYeVczKGh? MWLpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 NX7vc5FjOjZzM{exNFU>
Tca8113/PYM  MlrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXq5bGNQOi1{NfMAje69VQ>? NIrsPZE4OiCq MVzpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 MV6yOlE{PzFyNR?=
SKOV3 NGrGUFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvCZlA3OCCvZz;tcC=> NEXidG8yNTViZB?= MX;pcohq[mm2czDj[YxtKH[rYXLpcIl1gSC2aX3lJIRmeGWwZHXueIx6 NVy3coVUOjZzM{ewOFM>
SKOV3 M3XIdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLvNE01KM7:Zz;tcC=> NVj2T|Q{OjRxNEivO|IhcA>? MUTpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueIx6 NHjCTI4zPjF{NUK3Ny=>
SKOV3 NHjTXGRCeG:ydH;zbZMhSXO|YYm= MX:yJO69\y:vbB?= NV62S3g3PDhiaB?= MmSxbY5lfWOnczDhdI9xfG:|aYO= NFqxWlIzPjF{NUK3Ny=>
OSA NFXqNItEdG:wb3flcolkKEG|c3H5 MlnFNk42NzVizszN NIDyTZpz\XO3bITzJIlvKGyxd3XyJINwdG:weTDmc5Ju[XSrb36gZZMh[2:vcHHy[YQhfG9iZXn0bIVzKEKPSUGgd4lTVkFidILlZZRu\W62 NY\3fnM5OjZzMUC2NlA>
A549 NXLobXE{TnWldHnvckBCe3OjeR?= MmPiNE8zPS93MDFOwG0> NFnDWXczPCCq NYnlcm1Z\G:5boLl[5Vt[XSnczDtbXIuOjB3IHX4dJJme3Orb39CpC=> NEPkV40zPTlzN{OxOy=>
H1975 MmD2SpVkfGmxbjDBd5NigQ>? NFL1ZpAxNzJ3L{WwJO69VQ>? MYGyOEBp M1vifoRwf26{ZXf1cIF1\XNibXnSMVIxPSCneIDy[ZN{cW:wwrC= MXSyOVkyPzNzNx?=
A549 MmrUSpVkfGmxbjDBd5NigQ>? NVnDb4hIOC9{NT:1NEDPxE1? MX:yOEBp MmLSeZBz\We3bHH0[ZMhdWmULUKxPEBmgHC{ZYPzbY9v M1Th[lI2QTF5M{G3
H1975 MUTGeYN1cW:wIFHzd4F6 MWWwM|I2NzVyIN88US=> MYqyOEBp MYX1dJJm\3WuYYTld{BucVJvMkG4JIV5eHKnc4Ppc44> MWSyOVkyPzNzNx?=
A549 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PYdVI2KM7:TR?= NV7aNIo4OjRiaB?= MXjpcohq[mm2czDj[YxtKGe{b4f0bC=> M3jtO|I2QTF5M{G3
H1975 NH7RWVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfpR2wzPSEQvF2= MnviNlQhcA>? MVHpcohq[mm2czDj[YxtKGe{b4f0bC=> NGPyWIUzPTlzN{OxOy=>
MDA-MB-231 Mon0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fNXFAuOjJyIN88[{9udA>? NYGw[mNkPzJiaB?= M{DVXGlEPTEEoE2gPFYh|ryP NGX2WYgzPTh|N{[5NS=>
T47D M3O3T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjxWI0xNTJ{MDFOwIcwdWx? MmH3O|IhcA>? M3i4RmlEPTEEoE2gOFgvQSEQvF2= NFnENmQzPTh|N{[5NS=>
LCTCC Ml3QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3:zZWlEPTB;Mz645qCKyrWP MljrNlU4PzNzNke=
MCTCC NHfCfGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HRXmlEPTB;Mj645qCKyrWP NXr4NHk5OjV5N{OxOlc>
MegTCC NYDaempkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\UNYxKSzVyPUSuNgKBkcL3TR?= MYeyOVc4OzF4Nx?=
MonoTCC NVvPenNHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrtXFN6UUN3ME21MlbjiIoEtV2= M2SzeVI2Pzd|MU[3
MCF7 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfjRnhEOjBizszN MXK3NkBp NInJN2FqdmS3Y3XzJINmdGxiZHXheIghd2ZiSGCx{tIu\GWybHX0[YQhVUOINzDj[Yxtew>? NUSwW29TOjV5NkmwNlU>
A-549  NYHHTWtqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LYcVAvPSEQvF2= NVj0fpJuOjRiaB?= M1vmN2ROW00EoB?= MX3pcohq[mm2czDj[YxtKGe{b4f0bEB{cWewaX\pZ4FvfGy7 M{P5S|I2PzV3Nkmw
A-549  NFvzN2RCeG:ydH;zbZMhSXO|YYm= MXywMlUh|ryP MoXEOFghcA>? MXnEUXNQyqB? MkHMd4hwf3NiZXHycJkh[XCxcITvd4l{KG[nYYT1doV{KGmwY3z1[Ilv\yCkbHXiZolv\yCjbnSgZ4hzd22jdHnuJINwdmSnboPheIlwdg>? MnjRNlU4PTV4OUC=
A-549  M1n5cmZ2[3Srb36gRZN{[Xl? NVHCVHFuOC53IN88US=> M1u3O|Q5KGh? MliySG1UV8Li MVzzbI94eyCjYnXydoFvfCCvaXPyc5R2[nWuZTDkbZNzfXC2aX;u NFjzOoczPTd3NU[5NC=>
A-549  M1nR[2Z2[3Srb36gRZN{[Xl? NHz2ZVMxNjVizszN M{PqPVQ5KGh? M3TDfWROW00EoB?= NXfz[|NKcW6qaXLpeJMhd2ZiY3XscEBucWe{YYTpc47DqA>? NVTFeY42OjV5NUW2PVA>
RMG-1 NVLZPYJnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrTTWNpUUN3ME2yPE45KMLzIEOuOkBu\y:O MWOyOVczPjlzMx?=
FN-RMG-1 NEPicGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTRyLkWgxtEhPC5{IH3nM2wLKM7:TR?= MXqyOVczPjlzMx?=
RMG-1-hFUT NV20OHZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;rbVJKSzVyPUW4MlEhyrFiMj60JI1oN0x? M3;jRlI2PzJ4OUGz
FN-RMG-1-hFUT NWP1cnVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\GPHJ2UUN3ME2xNVgvQCEEsTCxN{45KG2pL1y= M4\KOFI2PzJ4OUGz
CHP-134  NHG2bG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fs[lEh|ryP MojZSG1UV8Li MYLpcohq[mm2czDzbYdvcW[rY3HueEBk\WyuIHfyc5d1cCClb33ibY5m\CC5aYToJGdUUzJ6M{CzO|E> NIPGdoEzPTZ3OES2Ny=>
IMR-32 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;pNUDPxE1? NEnKdphFVVORwrC= M1zDPYlvcGmkaYTzJJNq\26rZnnjZY51KGOnbHyg[5Jwf3SqIHPvcYJqdmWmIIfpeIghT1ONMkizNFM4OQ>? MkHvNlU3PTh2NkO=
CHP-134  NVLJXXdPTnWldHnvckBCe3OjeR?= NX;WbWY3OTBizszNxsA> NFjzNY5FVVORwrC= NH\4e2ZqdmS3Y3XzJIFxd3C2b4Ppd{B{cWewaX\pZ4FvfGy7IHPvcYJqdmWmIIfpeIghT1ONMkizNFM4OQ>? M4myflI2PjV6NE[z
IMR-32 MYnGeYN1cW:wIFHzd4F6 M2fIflExKM7:TdMg MYXEUXNQyqB? NHqxZmxqdmS3Y3XzJIFxd3C2b4Ppd{B{cWewaX\pZ4FvfGy7IHPvcYJqdmWmIIfpeIghT1ONMkizNFM4OQ>? MWmyOVY2QDR4Mx?=
A549 M{DQZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTsZWdUOC5{LUSwNFAh|ryP MorVO|IhcA>? MYDJR|UxRTF{NjFCtUA2NjBizszN NVPHO3VLOjV4MkWyOFM>
A549/CDDP MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2C2[lAvOi12MECwJO69VQ>? M2fld|czKGh? NU\xXHJGUUN3ME2yOFDDqMLzwrC0OU44KM7:TR?= M4H1c|I2PjJ3MkSz
H460  MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XUOlI1KGh? NG\JWYRFVVOR M3HzfmlEPTB;Nz65JO69VQ>? MnnjNlU2QTl7OUW=
H460  NVy3b|JwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVK3Mlkh|ryP M3HjXVI1KGh? M1Xad2ROW09? NGfOepd{cG:5czDhJJJi\Gmxc3Xud4l1cXqrbneg[YZn\WO2IITvJHguemG7cx?= M3r6N|I2PTl7OUm1
NRK-52E MlnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3H1WFczyqCqwrC= NELTZ5lKSzVyPUGwNEDDuSBzMj65JO69VQ>? MVKyOVU3PTZyMx?=
RGE NFrxdW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfvOYhTPzMEoHlCpC=> NHqweo5KSzVyPUKyJOKyKDdwNDFOwG0> MnzBNlU2PjV4MEO=
NRK-52E NE\PZ4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjaTpA3PzMEoHlCpC=> NVHx[YFYUUN6ME2xO|khyrFiOT61JO69VQ>? MYGyOVU3PTZyMx?=
RGE MlH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Ww[lczyqCqwrC= NX3ScHBLUUN6ME22N{DDuSB5LkSg{txO MnG0NlU2PjV4MEO=
SK-OV-3 MlPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjGO|IhcA>? MVjJR|UxRTFyND64JO69VQ>? MUCyOVUzODF|Mh?=
ES-2 MlPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mly5O|IhcA>? NWfhOI5PUUN3ME2xOE43KM7:TR?= NGG4SHozPTV{MEGzNi=>
OVCAR-8 NVTNdIFJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVi3NkBp Mm\YTWM2OD17Nj6wJO69VQ>? NWP5bItCOjV3MkCxN|I>
3AO NVXreJB2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfxUIhPPzJiaB?= M3nuXGlEPTB;NkOuOEDPxE1? MUKyOVUzODF|Mh?=
A2780 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\PO|IhcA>? NIrpWZZKSzVyPUG0OU44KM7:TR?= M4DOXlI2PTJyMUOy
SW626 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfCO|IhcA>? MXLJR|UxRTl5LkCg{txO MojLNlU2OjBzM{K=
OVCAR-3 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPLRmRVPzJiaB?= MVLJR|UxRTN{Lk[g{txO M4DqR|I2PTJyMUOy
A549 NV7Y[29[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HSXWlEPTB;MUWxMlU3KMLzIEWzMlA3KM7:TR?= M2HOVVI2Ojd5NE[x
4T1 NWezUnVFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXtVmtoUUN3ME24OE43OiEEsTCzNE4xPSEQvF2KJO69VQ>? NG\LSVgzPTJ5N{S2NS=>
BALB/3T3 M{LkS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEj4fnJKSzVyPUG0MlMxKMLzIE[uOlgh|ryP NUW4c2ozOjV{N{e0OlE>
B16 Mn;hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoX1TWM2OD14ND6zNEDDuSB4LkixJO69VQ>? MVWyOVI4PzR4MR?=
DU 145 Ml7QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTN3LkC0JOKyKDF5LkW0JO69VQ>? MWeyOVI4PzR4MR?=
FaDu NEK5UZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDwcWhKSzVyPUS1MlM6KMLzIEGxMlUxKM7:TR?= NH\ZcY8zPTJ5N{S2NS=>
HCV-29T MmPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvUbG9KSzVyPUS4MlU4KMLzIEKyMlQ6KM7:TR?= MlTlNlUzPzd2NkG=
HL-60 Mo\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TTWmlEPTB;MUGuNVAhyrFiND60O{DPxE1? NH;jNIszPTJ5N{S2NS=>
HT-29 NFm4Uo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHCTWM2OD16OT6xOkDDuSBzOD64OkDPxE1? NV\k[FVzOjV{N{e0OlE>
H146 NWH2PJBxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\1SnNLUUN3ME20PU43yrFzMz6xJO69VQ>? NVjSU2FSOjVzMkSyPFI>
H187 MnP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHHV41oUUN3ME2xNk44yrF{Lkeg{txO M4WyclI2OTJ2Mkiy
H128 Mo\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3K2eGlEPTB;MUC2MlTDuTlwNjFOwG0> MnnRNlUyOjR{OEK=
H69 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWj3bZJEUUN3ME23Ok46yrF{Nz64JO69VQ>? MUeyOVEzPDJ6Mh?=
H209 Mk\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfNTWM2OD1{NUiuNeKyQTlwODFOwG0> NHPGb40zPTF{NEK4Ni=>
DMS153 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPMTHNKSzVyPUW3MljDuTlwMjFOwG0> M1z3e|I2OTJ2Mkiy
H526 M1T3fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTdwMtMxNU44KM7:TR?= MUKyOVEzPDJ6Mh?=
DMS114 M{Tw[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NET0eIFKSzVyPUi1MljDuTF{Lkig{txO MoHjNlUyOjR{OEK=
DMS53 MnfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTFTWM2OD1zNE[uNuKyOzZwNDFOwG0> MnHsNlUyOjR{OEK=
HeLa NH7l[IFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPHcXc6PS16MDFOwG0> Ml;0bY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> NF;pRpozPTFyOUO2NC=>
MCF-7 Ml7hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzFNpg2NThyIN88US=> MWXpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 MX:yOVExQTN4MB?=
MDA-MB-231 NXf6TmxyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnn5OU05OCEQvF2= MXzpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 NFfpclQzPTFyOUO2NC=>
CaOV3 MmLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzYbW84OiCq NGfLeFhKSzVyPUi2MlEh|ryP NGqwfpYzPTB4OEi0PS=>
OVCAR-3 MkTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mon1O|IhcA>? MU\JR|UxRTF5OT61JO69VQ>? MXGyOVA3QDh2OR?=
OVCAR-5 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYL2OFRJPzJiaB?= MojJTWM2OD15NT63JO69VQ>? M4nJ[FI2ODZ6OES5
SKOV-3 NULXU2lHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfSXZU4OiCq NGfnb3pKSzVyPUWwOEDPxE1? NV3YUItQOjVyNki4OFk>
OVCAR-4 M3PzeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWm3NkBp MYXJR|UxRTJ7MD62JO69VQ>? MY[yOVA3QDh2OR?=
OVCAR-8 NHX5Uo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGflOIk4OiCq MX;JR|UxRTZ7MD6yJO69VQ>? NFroW|czPTB4OEi0PS=>
MA148 NXPjfHNkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXqyOEBp M1zpNWlEPTB;OEOuOwKBkcLz4pEJNU41KM7:Zz;tcC=> NWfoPI9tOjR6M{GwPVE>
A549 M1y4Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLZVYpEOjRiaB?= MlrETWM2OD15N{[uNQKBkcLz4pEJNU46KM7:Zz;tcC=> NFq3PYEzPDh|MUC5NS=>
MDA-MB-231 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWOyOEBp M{X6fGlEPTB;N{S4MlDjiIoEsfMAjVEvOSEQvHevcYw> MUWyOFg{OTB7MR?=
NCI-ADR/RES  NWrxZ|F4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTLSpRyOjRiaB?= MmXMTWM2OD1zN{WzMlDjiIoEsfMAjVQvPCEQvHevcYw> NEO0OGszPDh|MUC5NS=>
MA148 M4rqfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXtZnptPDhiaB?= M1jrOGlEPTB;MkiuNgKBkcLz4pEJNU4xKM7:Zz;tcC=> MkHTNlQ5OzFyOUG=
A549 M372NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zIN|Q5KGh? MY\JR|UxRTFzOD6w5qCKyrIkgJmxMlIh|rypL33s MV2yOFg{OTB7MR?=
MDA-MB-231 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\VOFghcA>? MWrJR|UxRTF6Mz6w5qCKyrIkgJmxMlIhKM7:Zz;tcC=> M2TKOlI1QDNzMEmx
NCI-ADR/RES  NEfrOFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk[xOFghcA>? MXXJR|UxRTF7Mz6w5qCKyrIkgJmxMlkh|rypL33s MkXhNlQ5OzFyOUG=
MA148 M4Kzc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnSO|IhcA>? NWr5VmJQUUN3ME2xN{446oDLwsJihKkyNjJizsznM41t MoTINlQ5OzFyOUG=
A549 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHOW5k4OiCq NHLE[|VKSzVyPU[0MlPjiIoEsfMAjVEvOSEQvHevcYw> NFrnRnUzPDh|MUC5NS=>
MDA-MB-231 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nuSFczKGh? NFjHS5ZKSzVyPUm5MlXjiIoEsfMAjVEvOSEQvHevcYw> Mk\ENlQ5OzFyOUG=
NCI-ADR/RES  NH3kTndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jId|czKGh? MkLVTWM2OD1|Nz605qCKyrIkgJmxMlch|rypL33s NVz3ZXRXOjR6M{GwPVE>
A549 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LCZlczKGh? M3nWZWROW09? MmPKTWM2OD1zNUKuOFA6KM7:TR?= M2XqdlI1PzJzM{Kz
NCI-H157 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW[3NkBp M1T3SWROW09? NFHnSm5KSzVyPUi5Mlk4PyEQvF2= MmXxNlQ4OjF|MkO=
PC9 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;4O|IhcA>? MlrBS2M2OD15MT62xtE6NjViwsXN NX\oVZBlOjR4MUi4NFk>
A549  MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HDRlczKGh? NF\sZVRISzVyPUGzOuKyOzFwNjFCuW3DqA>? NFO3VZIzPDZzOEiwPS=>
PC9 MoCzRZBweHSxc3nzJGF{e2G7 M4fvXlExOCEEtV2= M{XVVlczKGh? NYiwfJFUcW6mdXPld{BieG:ydH;zbZM> NVr4W5c6OjR4MUi4NFk>
A549  NXrVSZRnSXCxcITvd4l{KEG|c3H5 NFH1Z5EyODBiwsXN MnvqO|IhcA>? NF;0S4JqdmS3Y3XzJIFxd3C2b4Ppdy=> NV7pPWVxOjR4MUi4NFk>
A549 M3z4WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYWyOEBp M3XWdGlEOTB;MT60O|Yhdk1? Mm\ZNlQ{QTZ2M{e=
H1299 NGrseVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\jO2pCOjRiaB?= MUfJR|ExRTBwNESzJI5O MVGyOFM6PjR|Nx?=
HCC15 MnLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorRNlQhcA>? MmDpTWMyOD1yLkO0OkBvVQ>? NF7wbVIzPDN7NkSzOy=>
H157 M{HMZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfDNlQhcA>? NFLnbVRKSzFyPUCuPFEhdk1? M{L2S|I1Ozl4NEO3
A2780 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTF2LkFihKnDueLCiUGuOEDPxE1? NEjtV5ozPDJyOU[5Ny=>
A2780cisR MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\PTWM2OD12OD655qCKyrIkgJmzMlkh|ryP M3jlOVI1OjB7Nkmz
A2780ZD0473R NXj1[nMzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTZ2LkdihKnDueLCiUOuNkDPxE1? MkjmNlQzODl4OUO=
SKOV-3 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33pSGlEPTB;NEOuOQKBkcLz4pEJN{46KM7:TR?= MYSyOFIxQTZ7Mx?=

... Click to View More Cell Line Experimental Data

In vivo In A2780 tumor xenografts, Carboplatin (60 mg/kg via i.p.) given as single agents shows a modest antitumor effect with the relative tumor volumes on day 6 of 8.4 compared to the control of 11.9, and the day 6 tumor weights relative to control (T/C) of 67%. [1] For the VC8 (Brca2-deficient) xenografts, Carboplatin treatment delays tumor growth and reduces tumor mass by 42% compared to the vehicle group. [3]

Protocol

Cell Research:

[1]

+ Expand
  • Cell lines: A2780, SKOV3, IGROV-1 and HX62
  • Concentrations: 0-200 μM
  • Incubation Time: 72 hours
  • Method:

    3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) assays: Exponentially growing A2780, SKOV3, IGROV-1 and HX62 ovarian cancer cells are plated in 96 well plates. A range of drug concentrations are added and the plates are incubated for 72 hours to allow for 3–4 doubling times. Each experiment is carried out in triplicate. Sulforhodamine B (SRB) assays: Exponentially growing A2780 cells are plated in 96 well microtitre plates. For experiments studying concomitant exposure, cells are exposed to increasing concentrations of both drugs for 96 hours. For experiments studying the effect of sequence of exposure to 17-AAG or carboplatin cells are exposed to increasing concentrations of 17-AAG or carboplatin for 24 hours. A period of 24-hour exposure to the first agent is chosen so that the A2780 cells would be exposed to the first drug for at least one doubling time (18-24 hours). The cells are then washed with sterile phosphate buffered saline and the medium is replenished. Following this, the second drug (to which the cells are not exposed to in the first 24 hours) or medium is added for 96 hours. All experiments are carried out in triplicate. The results of combination studies are analyzed using the well-established principles of median effect analysis method. The effects of the combination are calculated using an in-house spreadsheet.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: The A2780 human ovarian cancer cell line is grown as a subcutaneous xenograft in female athymic NCr nude mice (nu/nu) in each flank.
  • Formulation: Carboplatin is dissolved in 43% ethanol, 33% polypropylene glycol and 24% cremaphor diluted 1:7 with sterile water.
  • Dosages: ≤60 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro Water 14 mg/mL warmed (37.71 mM)
DMSO Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
water
14mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 371.25
Formula

C6H12N2O4Pt

CAS No. 41575-94-4
Storage powder
Synonyms JM-8, CBDCA, NSC 241240

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01828736 Completed Recurrent Bladder Cancer|Stage IV Bladder Cancer|Transitional Cell Carcinoma of the Bladder Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie|Roche Pharma AG February 9, 2004 Phase 2
NCT02124902 Recruiting Triple Negative Breast Neoplasms Washington University School of Medicine July 7, 2014 Phase 2
NCT02941523 Not yet recruiting Cancer Noxopharm Limited March 6, 2017 Phase 1|Phase 2
NCT01352962 Active, not recruiting Urethral Neoplasms|Neoplasms, Urethral|Ureter Cancer|Cancer of the Urethra|Urethral Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 5, 2011 Phase 1
NCT03032614 Not yet recruiting Breast Cancer Stage IV|Ovarian Cancer|BRCA1 Mutation|BRCA2 Mutation The University of Texas Health Science Center at San Antonio March 31, 2017 Phase 2
NCT01419548 Withdrawn Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 29, 2011 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Can you advise what solvent to use and the concentration for S1215 for in vitro use?

  • Answer:

    DMSO will affact the activity of platinum agents. For in vitro use, according to our experience in dissolving this compound, we didn't find any solvent can dissolve it alone, but S1215 can be dissolved in co-solvent ethanol:water=1:2 at 15 mg/ml. We didn't test the stablility of the drug in such vehicle, so it is recommended to prepare the solution just before use.

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Tags: buy Carboplatin | Carboplatin supplier | purchase Carboplatin | Carboplatin cost | Carboplatin manufacturer | order Carboplatin | Carboplatin distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID